Enterprise of the Institute of Poliomyelitis and Viral Encephalitis. M.P.Chumakova carried out a complete modernization of production

By the end of 2014, at the enterprise of the Institute of Poliomyelitis and Viral Encephalitis. MP Chumakov completed the modernization and technical re-equipment of all production units in accordance with international GMP standards. The available facilities, software and spare parts are sufficient to provide the entire population of the Russian Federation with the necessary drugs.

Technical modernization has established a number of functional systems for training and professional development of personnel, for auditing suppliers of equipment, raw materials and consumables; on feedback from customers, post-marketing monitoring of the quality of released vaccines and pharmacovigilance for the occurrence of possible side effects from their use.

After the completion of the technical re-equipment, the enterprise is a modern research and production complex that produces medical products for the prevention, diagnosis and treatment of viral diseases. The enterprise produces vaccines against poliomyelitis, yellow fever, rabies, tick-borne encephalitis, and diagnostic sera. On the Russian market, drugs produced by the Federal State Unitary Enterprise “Enterprise of the Institute of Poliomyelitis and Viral Encephalitis named after A.I. M.P. Chumakov” occupy up to 80% of the market demand in their segments.

“For many years, our company has been providing Russia and the CIS countries with vaccines that fully meet international quality standards. The technical modernization of production will allow us not only to increase the volume of products for the domestic market, but also to increase Russia’s share in the supply of vaccines for international charitable organizations such as WHO and Unicef ​​up to 40%, ”said the director of the enterprise of the Institute of Poliomyelitis and Viral Encephalitis. M.P. Chumakov Aidar Ishmukhametov.

Currently, the company is the largest manufacturer and exporter of vaccines in Russia and the CIS countries and the only one who has WHO permission to supply vaccines for charitable programs through UN agencies (WHO, UNICEF, PAHO).

Bringing the production unit in line with international GMP standards brought the enterprise of the Institute of Poliomyelitis and Viral Encephalitis named after. M.P. Chumakov in the lead among domestic and foreign manufacturers. As a result of the technical re-equipment of the enterprise, it became possible to develop new vaccines that have no analogues in the world.

Enterprise of the Institute. MP Chumakova is developing a domestic vaccine As part of the replacement of foreign inactivated vaccine, which is now purchased by the state under the National Immunization Schedule, the Enterprise of the Institute of Poliomyelitis. M.P. Chumakov is developing a domestic vaccine, which is a strategically important drug. In 2 years, the vaccine will be launched into mass production. It is expected that the Russian drug will be 3-5 times cheaper than foreign analogues.

Currently, the Enterprise of the M.P. Chumakov Polio Institute is faced with the task of replacing foreign vaccines with domestic ones in order to ensure the national security of the country and save budgetary funds. Thus, the cost of the National Immunization Schedule for the current year is more than 10 billion rubles, while only the cost of two drugs produced with the participation of foreign companies “eats up” 60% of this budget.

“Domestic vaccines are much cheaper than imported ones – now the state buys them at a price almost lower than the cost. Since manufacturing enterprises are state institutions, and, as a rule, the only suppliers of the drug on the market, they do not only sell their goods, but perform an important social function to protect the national security of Russia, ”said the director of the Enterprise of the Institute of Poliomyelitis and Viral Encephalitis named after. M.P. Chumakov Aidar Ishmukhametov.

Also, the Enterprise of the Institute of Poliomyelitis and Viral Encephalitis. M.P. Chumakov RAMS launched the production of the first vaccine in Russia for the prevention of tick-borne encephalitis – Klesch-E-Vak, intended for children from 1 to 16 years of age. This drug, which meets all domestic and international standards, is much more affordable for the average consumer than the imported analogue.